Results 31 to 40 of about 45,806 (246)

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

New England Journal of Medicine, 2019
BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune‐mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis ...
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J. Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, Debjit Biswas, H. de Winter, R. Zeldin   +12 more
semanticscholar   +1 more source

Treatment of thrombotic thrombocytopenic purpura

Terapevticheskii arkhiv, 2021
The review discusses approaches to treatment of congenital thrombotic thrombocytopenic purpura (TTP) or Upshaw-Schulman syndrome. In congenital TTP, plasma transfusions are sufficient. Such treatment options as plasma exchange, administration of clotting factor VIII concentrate, recombinant ADAMTS13, are also used.
Gennadii M. Galstyan, Alexei A. Maschan, Elizaveta E. Klebanova, Irina I. Kalinina   +3 more
openaire   +7 more sources

Thrombotic Thrombocytopenic Purpura in Dengue Fever

Acta Medica Indonesiana, 2021
Thrombotic thrombocytopenic purpura is a rare but life threatening medical condition. Early recognition and treatment of thrombotic thrombocytopenic purpura is important especially in patients who do not present with the classic pentad to reduce the high
Tze Yuan Tee, Rizna Abdul Cader
doaj  

Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005 [PDF]

, 2007
The prevalence, incidence and outcomes of haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopaenic purpura (TTP) are not well established in adults or children from prospective studies. We sought to identify both outcomes and current management
D. YOUNG, Hosler, K. G. J. POLLOCK, Marques, Sadler, T. J. BEATTIE, Tarr, Van Dyck, W. T. A. TODD   +8 more
core   +2 more sources

Thrombotic thrombocytopenic purpura [PDF]

The Journal of the American Osteopathic Association, 1989
Once formerly thought to be a rare disorder, thrombotic thrombocytopenic purpura (TTP) is becoming increasingly recognized. It is characterized by a pentad of clinical findings, including microangiopathic hemolytic anemia, thrombocytopenic purpura, neurologic and renal abnormalities, and fever.
openaire   +3 more sources

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

Haematologica, 2016
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13.
Wenjing Cao, Huy P. Pham, Lance A. Williams, Jenny McDaniel, Rance C. Siniard, Robin G. Lorenz, Marisa B. Marques, X. Long Zheng   +7 more
doaj   +1 more source

Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. [PDF]

, 2009
The activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome.
Bõze, Tamás, Cervenak, László, Derzsy, Zoltán, Gombos, Tímea, Hársfalvi, Jolán, Makó, Veronika, Molvarec, Attila, Prohászka, Zoltán, Rigó, János, Udvardy, Miklós László   +9 more
core   +1 more source

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood, 2020
Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation
George Goshua, P. Sinha, J. Hendrickson, C. Tormey, Pavan K Bendapudi, A. Lee   +5 more
semanticscholar   +1 more source

Thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2005
This overview summarizes the history of thrombotic thrombocytopenic purpura (TTP) from its initial recognition in 1924 as a most often fatal disease to the discovery in 1997 of ADAMTS-13 deficiency as a major risk factor for acute disease manifestation.
J. A. Kremer Hovinga, Bernhard Lämmle, Lorenzo Alberio   +2 more
openaire   +5 more sources

Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience

Haematologica, 2012
Background Acquired thrombotic thrombocytopenic purpura is still associated with a 10–20% death rate. It has still not been possible to clearly identify early prognostic factors of death.
Ygal Benhamou, Cyrielle Assié, Pierre-Yves Boelle, Marc Buffet, Rana Grillberger, Sandrine Malot, Alain Wynckel, Claire Presne, Gabriel Choukroun, Pascale Poullin, François Provôt, Didier Gruson, Mohamed Hamidou, Dominique Bordessoule, Jacques Pourrat, Jean-Paul Mira, Véronique Le Guern, Claire Pouteil-Noble, Cédric Daubin, Philippe Vanhille, Eric Rondeau, Jean-Bernard Palcoux, Christiane Mousson, Cécile Vigneau, Guy Bonmarchand, Bertrand Guidet, Lionel Galicier, Elie Azoulay, Hanspeter Rottensteiner, Agnès Veyradier, Paul Coppo   +30 more
doaj   +1 more source